Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PMV Pharmaceuticals, Inc. (PMVP : NSDQ)
 
 • Company Description   
PMV Pharmaceuticals Inc.is a precision oncology company. It engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. PMV Pharmaceuticals Inc.is headquartered in Cranbury, New Jersey.

Number of Employees: 54

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.26 Daily Weekly Monthly
20 Day Moving Average: 387,226 shares
Shares Outstanding: 53.33 (millions)
Market Capitalization: $67.20 (millions)
Beta: 1.41
52 Week High: $1.88
52 Week Low: $0.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.89% -16.19%
12 Week -8.03% -14.98%
Year To Date 0.80% -5.85%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 Alexander Park Drive Suite 301
-
Princeton,NJ 08540
USA
ph: 609-642-6670
fax: -
investors@pmvpharma.com http://www.pmvpharma.com
 
 • General Corporate Information   
Officers
David H. Mack - President; Chief Executive Officer andDirector
Richard Heyman - Director and Chairman of the Board ofDirectors
Michael Carulli - Chief Financial Officer
Arnold Levine - Director
Carol Gallagher - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 69353Y103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/06/26
Share - Related Items
Shares Outstanding: 53.33
Most Recent Split Date: (:1)
Beta: 1.41
Market Capitalization: $67.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.45 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.76
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/26 - -68.98
12/31/25 - -59.07
09/30/25 - -55.34
ROA
03/31/26 - -62.70
12/31/25 - -54.19
09/30/25 - -51.01
Current Ratio
03/31/26 - 11.14
12/31/25 - 10.09
09/30/25 - 10.77
Quick Ratio
03/31/26 - 11.14
12/31/25 - 10.09
09/30/25 - 10.76
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Book Value
03/31/26 - 1.65
12/31/25 - 1.97
09/30/25 - 2.28
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©